Boston Scientific cuts full-year profit outlook on Watchman weakness
BSX Boston Scientific Corp
$46.04 -0.04%
차트·분석 보기 → - 1Boston Scientific (BSX) exceeded guidance with Q2 net sales of $5.44 billion and adjusted EPS of $0.86, but lowered its full-year profit outlook
- 2Cut its full-year adjusted EPS range to $3.28–$3.32 from $3.34–$3.41, and organic revenue growth to 5%–6% from 6.5%–8%
- 3Watchman stand-alone procedures declined as combination with other cardiac procedures rose, and that revenue is expected to remain largely flat in Q2 and Q3
This 3-line summary is compiled from the report below.
Investing.com +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다